Literature DB >> 6123303

Glutamate in schizophrenics and healthy controls.

W F Gattaz, D Gattaz, H Beckmann.   

Abstract

Cerebrospinal fluid (CSF) glutamate levels were measured in 28 paranoid schizophrenic patients and 15 healthy individuals. From the 28 patients 15 were treated with neuroleptic drugs and 13 did not take any drugs. No significant difference was found between glutamate in patients without neuroleptics and controls. However, CSF glutamate was significantly higher in patients taking neuroleptics than in controls (P less than 0.001) or in patients without neuroleptics (P less than 0.01). This and other data from the literature indicate that enhanced levels of cerebral glutamate may be significant for the antipsychotic efficacy of neuroleptic drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123303     DOI: 10.1007/bf00343292

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  8 in total

1.  [Treatments with glutamic acid].

Authors:  H GIESE
Journal:  Munch Med Wochenschr       Date:  1953-08-21

Review 2.  Glutamic acid as a synaptic transmitter in the nervous system. A review.

Authors:  J L Johnson
Journal:  Brain Res       Date:  1972-02-11       Impact factor: 3.252

3.  Sodium ion movements and the spontaneous and electrically stimulated release of ( 3 H)GABA and ( 14 C)glutamic acid from rat cortical slices.

Authors:  J P Hammerstad; R W Cutler
Journal:  Brain Res       Date:  1972-12-12       Impact factor: 3.252

4.  Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods.

Authors:  L T Graham; M H Aprison
Journal:  Anal Biochem       Date:  1966-06       Impact factor: 3.365

5.  Metabolic response of synaptosomes to electrical stimulation: release of amino acids.

Authors:  H F Bradford
Journal:  Brain Res       Date:  1970-04-14       Impact factor: 3.252

Review 6.  An overview of glutamate as a neurotransmitter.

Authors:  C W Cotman; A Foster; T Lanthorn
Journal:  Adv Biochem Psychopharmacol       Date:  1981

7.  Activation of dopamine receptors inhibits calcium-dependent glutamate release from cortico--striatal terminals in vitro.

Authors:  G F Rowlands; P J Roberts
Journal:  Eur J Pharmacol       Date:  1980-03-21       Impact factor: 4.432

8.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

Authors:  J S Kim; H H Kornhuber; W Schmid-Burgk; B Holzmüller
Journal:  Neurosci Lett       Date:  1980-12       Impact factor: 3.046

  8 in total
  5 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  High resolution crystal structures of human kynurenine aminotransferase-I bound to PLP cofactor, and in complex with aminooxyacetate.

Authors:  Naveed A Nadvi; Noeris K Salam; Joohong Park; Fady N Akladios; Vimal Kapoor; Charles A Collyer; Mark D Gorrell; William Bret Church
Journal:  Protein Sci       Date:  2017-03-06       Impact factor: 6.725

Review 3.  Chemistry, physiology and neuropsychology of schizophrenia: towards an earlier diagnosis of schizophrenia I.

Authors:  H H Kornhuber
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

4.  Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.

Authors:  H Beckmann; G P Reynolds; M Sandler; P Waldmeier; J Lauber; P Riederer; W F Gattaz
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

5.  Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice.

Authors:  Suzanne A Brody; Mark A Geyer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.